Led by $1.2bn private equity deal with Natus Medical, North America’s medical devices industry saw a drop of 36.30% in cross border deal activity during Q2 2022, when compared to the last four-quarter average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 43 cross border deals worth $2.5bn were announced for the region during Q2 2022, against the last four-quarter average of 67.50 deals.
Of all the deal types, venture financing saw most activity in Q2 2022 with 26 deals, representing a 60.5% share for the region.
In second place was M&A with 14 deals, followed by private equity deals with three transactions, respectively capturing a 32.6% and 7% share of the overall cross border deal activity for the quarter.
In terms of value of cross border deals, private equity was the leading category in North America’s medical devices industry with $1.2bn, while venture financing and M&A deals totalled $982.44m and $283.1m, respectively.
North America medical devices industry cross border deals in Q2 2022: Top deals
The top five medical devices cross border deals accounted for a 78.2% share of the overall value during Q2 2022.
The combined value of the top five cross border deals stood at $1.93bn, against the overall value of $2.5bn recorded for the quarter.
1) ArchiMed $1.2bn private equity deal with Natus Medical
2) The $300m venture financing of Biofourmis by CVS Health,Export Development Bank of Iran,General Atlantic,Mass Mutual Ventures,Openspace Ventures,Sequoia Capital and SoftBank Vision Fund II
3) Guardant Health $177.8m acquisition deal with Guardant Health AMEA
4) The $150m venture financing of BostonGene by Impact Investment Partners,Japan Industrial Partners and NEC
5) Charles River Ventures,GV Management Co,Insight Partners,Kleiner Perkins,Scale Ventures,Sozo Ventures,Susa Ventures,Threshold Ventures and Tiger Global Management $100m venture financing deal with Viz.ai